These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29941432)

  • 1. The evolving epidemiology of
    Katz KC; Golding GR; Choi KB; Pelude L; Amaratunga KR; Taljaard M; Alexandre S; Collet JC; Davis I; Du T; Evans GA; Frenette C; Gravel D; Hota S; Kibsey P; Langley JM; Lee BE; Lemieux C; Longtin Y; Mertz D; Mieusement LMD; Minion J; Moore DL; Mulvey MR; Richardson S; Science M; Simor AE; Stagg P; Suh KN; Taylor G; Wong A; Thampi N;
    CMAJ; 2018 Jun; 190(25):E758-E765. PubMed ID: 29941432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality.
    Miller M; Gravel D; Mulvey M; Taylor G; Boyd D; Simor A; Gardam M; McGeer A; Hutchinson J; Moore D; Kelly S
    Clin Infect Dis; 2010 Jan; 50(2):194-201. PubMed ID: 20025526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.
    Scardina T; Labuszewski L; Pacheco SM; Adams W; Schreckenberger P; Johnson S
    Infect Control Hosp Epidemiol; 2015 Mar; 36(3):280-6. PubMed ID: 25695169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile infection: Description of NAP1/027 and non NAP1/027 strains in a high complexity center in Cali, Colombia, 2012-2015.
    Oñate-Gutiérrez JM; Segura J; Correa A; Cantor E; Villegas MV
    Biomedica; 2019 May; 39(s1):63-70. PubMed ID: 31529849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.
    Bauer KA; Johnston JEW; Wenzler E; Goff DA; Cook CH; Balada-Llasat JM; Pancholi P; Mangino JE
    Anaerobe; 2017 Dec; 48():1-6. PubMed ID: 28645479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.
    López-Ureña D; Quesada-Gómez C; Montoya-Ramírez M; del Mar Gamboa-Coronado M; Somogyi T; Rodríguez C; Rodríguez-Cavallini E
    Emerg Microbes Infect; 2016 May; 5(5):e42. PubMed ID: 27165560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAP1 strain type predicts outcomes from Clostridium difficile infection.
    See I; Mu Y; Cohen J; Beldavs ZG; Winston LG; Dumyati G; Holzbauer S; Dunn J; Farley MM; Lyons C; Johnston H; Phipps E; Perlmutter R; Anderson L; Gerding DN; Lessa FC
    Clin Infect Dis; 2014 May; 58(10):1394-400. PubMed ID: 24604900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare-Associated Clostridium difficile Infections and Strain Diversity in Pediatric Hospitals in the Canadian Nosocomial Infection Surveillance Program, 2007-2011.
    Le Saux N; Gravel D; Mulvey M; Moore D; Langley JM; Richardson S; Quach C; Choi KB; Miller M; Katz K;
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):e151-4. PubMed ID: 26407250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007.
    Karlowsky JA; Zhanel GG; Hammond GW; Rubinstein E; Wylie J; Du T; Mulvey MR; Alfa MJ
    J Med Microbiol; 2012 May; 61(Pt 5):693-700. PubMed ID: 22301615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.
    Pépin J; Valiquette L; Alary ME; Villemure P; Pelletier A; Forget K; Pépin K; Chouinard D
    CMAJ; 2004 Aug; 171(5):466-72. PubMed ID: 15337727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of Clostridium difficile in surgical patients in the United States.
    Zerey M; Paton BL; Lincourt AE; Gersin KS; Kercher KW; Heniford BT
    Surg Infect (Larchmt); 2007 Dec; 8(6):557-66. PubMed ID: 18171114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec.
    Hubert B; Loo VG; Bourgault AM; Poirier L; Dascal A; Fortin E; Dionne M; Lorange M
    Clin Infect Dis; 2007 Jan; 44(2):238-44. PubMed ID: 17173224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB
    J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host and pathogen factors for Clostridium difficile infection and colonization.
    Loo VG; Bourgault AM; Poirier L; Lamothe F; Michaud S; Turgeon N; Toye B; Beaudoin A; Frost EH; Gilca R; Brassard P; Dendukuri N; Béliveau C; Oughton M; Brukner I; Dascal A
    N Engl J Med; 2011 Nov; 365(18):1693-703. PubMed ID: 22047560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.
    Pépin J; Valiquette L; Gagnon S; Routhier S; Brazeau I
    Am J Gastroenterol; 2007 Dec; 102(12):2781-8. PubMed ID: 17900327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characteristics of Clostridium difficile infection in a high complexity hospital and report of the circulation of the NAP1/027 hypervirulent strain in Colombia].
    Gualtero SM; Abril LA; Camelo N; Sanchez SD; Davila FA; Arias G; Silva E; Bustos IG; Josa DF; Torres IC; Zambrano LC; Pareja MJ
    Biomedica; 2017 Dec; 37(4):466-472. PubMed ID: 29373767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spread of epidemic Clostridium difficile NAP1/027 in Latin America: case reports in Panama.
    López-Ureña D; Quesada-Gómez C; Miranda E; Fonseca M; Rodríguez-Cavallini E
    J Med Microbiol; 2014 Feb; 63(Pt 2):322-324. PubMed ID: 24287669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Clostridium difficile Ribotypes Circulating in Australian Hospitals and Communities.
    Furuya-Kanamori L; Riley TV; Paterson DL; Foster NF; Huber CA; Hong S; Harris-Brown T; Robson J; Clements AC
    J Clin Microbiol; 2017 Jan; 55(1):216-225. PubMed ID: 27807147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
    Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB
    Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
    Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
    J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.